Articles related to CHEMOTHERAPY

In a recent phase II trial, patients with untreated metastatic pancreatic ductal adenocarcinoma receiving sequential nab-P/Gem-mFOLFOX experienced a median overall survival of 13.2 months, compared to 9.7 months in those receiving standard nab-P/Gem treatment, indicating a notable improvement in survival outcomes.

In a recent phase 3 trial, a low-dose chemotherapy regimen demonstrated noninferior efficacy to standard-dose regimens in pediatric AML patients, while significantly reducing non-hematologic toxicities, an important consideration in pediatric oncology.

In a recent study, researchers found that, although pembrolizumab increased the pathological complete response in gastric cancer patients, it did not significantly improve event-free survival.

The study’s findings suggest that ibrutinib–venetoclax therapy could potentially revolutionize the treatment of CLL. With a significant reduction in disease progression or death at a median of 43.7 months, this therapy could offer a promising alternative to the standard FCR regimen.

The GCIG INTERLACE study has demonstrated a significant improvement in 5-year survival rates in advanced cervical cancer, from 72% to 80%, with the addition of induction chemotherapy to standard-of-care chemoradiation.

The study underscores the potential of osimertinib-chemotherapy combination as a first-line treatment in EGFR-mutated advanced NSCLC, demonstrating a significant improvement in progression-free survival and response rate compared to osimertinib monotherapy.